SCIENTURE HOLDINGS, INC. (SCNX) Q3 Revenue Rose 113% YoY to $1.25M

Scienture Holdings reported Q3 2026 revenue of $1.25M, up 113% YoY and 265% sequentially. The growth was driven by the August launch of REZENOPY, which generated $925K in net product revenue. The company also cited sales of Arbli as a contributing factor.

Original reporting
Published Nov 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SCIENTURE HOLDINGS, INC. (SCNX) Q3 Revenue Rose 113% YoY to $1.25M — source image
Decision brief

The 30-second read

$SCNXNeutralLow
01

Why it matters

The disclosed revenue growth is a primary earnings update but the absolute numbers are too small to drive significant market moves.

02

Market read

Micro‑cap earnings release with high growth percentages but negligible dollar impact; limited trading relevance.

03

What to watch

Potential future profitability hinges on repeat orders and distribution expansion, which remain uncertain.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

SCNX is a commercial‑stage biotech reporting its Q3 2026 results for the first time.

Company-level read

Ticker impact

$SCNXNeutralMedium confidence
Context

Q3 2026 revenue rose 113% YoY to $1.25M, driven by REZENOPY shipments.

Expected impact

modest upside as market prices in strong growth, but limited by micro‑cap liquidity

Evidence & confidence

Growth percentages are impressive, yet $1.25M revenue is trivial for a listed company, so any price reaction is likely muted.

Market effects

Limited impact on the broader biotech/health sector; growth is company‑specific.

No discernible regional effect.

Minimal; micro‑cap news does not influence global markets.

Counterpoint

Investors may view the tiny revenue base as a red flag, questioning sustainability of growth.

Key entities

  • SCIENTURE HOLDINGS, INC.

    Issuer of the earnings release.

  • REZENOPY

    New product generating the bulk of Q3 revenue.

Related articles

$SCNXMed

Scienture Holdings, Inc. (SCNX): Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential…

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additi

$SCNXMed

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat

$SCNXMedAI 8/10

Scienture Holdings, Inc.: SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.

$SCNXMedAI 8/10

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

Scienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.

$SCNXMed

Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up

Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.